The clinicopathological and prognostic impact of 14-3-3 protein isoforms expression in human cholangiocarcinoma by immunohistochemistry

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1253-1259

  Wu, Qiao ^a   Liu, Chang Zheng ^b   Tao, Lian Yuan ^a   Yu, Lan ^a   Liu, Wei ^a   Chen, Song Sen ^b   He, Xiao Dong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

14 3 3 isoforms; Cholangiocarcinoma; Immunohistochemistry; Malignant characteristics

Indexed keywords

PROTEIN 14 3 3;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CANCER STAGING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR VOLUME; UPREGULATION;

14-3-3 PROTEINS; ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR BURDEN; UP-REGULATION;

EID: 84873025979     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1253     Document Type: Article

References (32)

1. Fava G (2010). Molecular mechanisms of cholangiocarcinoma. World J Gastrointest Pathophysiol, 1, 12-22.
2. Guweidhi A, Kleeff J, Giese N, et al (2004). Enhanced expression of 14-3-3sigma in pancreatic cancer and its role in cell cycle regulation and apoptosis. Carcinogenesis, 25, 1575-85.
3. Iwata N, Yamamoto H, Sasaki S, et al (2000). Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene, 19, 5298-302.
4. Jeanteur P (2000). [14-3-3sigma (stratifin), a potential tumor suppressor frequently inactivated by methylation in cancer of the breast]. Bull Cancer, 87, 525.
5. Keshamouni VG, Michailidis G, Grasso CS, et al (2006). Differential protein expression profiling by iTRAQ- 2DLC-MS/MS of lung cancer cells undergoing epithelialmesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res, 5, 1143-54.
6. Kilani RT, Maksymowych WP, Aitken A, et al (2007). Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol, 34, 1650-7.
7. Lee EK, Lee YS, Lee H, Choi CY, Park SH (2009). 14-3-3epsilon protein increases matrix metalloproteinase-2 gene expression via p38 MAPK signaling in NIH3T3 fibroblast cells. Exp Mol Med, 41, 453-561.
8. Liang S, Xu Y, Shen G, et al (2009). Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation. Electrophoresis, 30, 4152-62.
9. Lim JH (2003). Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. AJR Am J Roentgenol, 181, 819-27.
10. Martin D, Brown-Luedi M, Chiquet-Ehrismann R (2003). Tenascin-C signaling through induction of 14-3-3 tau. J Cell Biol, 160, 171-5.
11. Miyakawa S, Ishihara S, Horiguchi A, et al (2009). Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from, 1998 to, 2004 in Japan. J Hepatobiliary Pancreat Surg, 16, 1-7.
12. Mosconi S, Beretta GD, Labianca R, et al (2009). Cholangiocarcinoma. Crit Rev Oncol Hematol, 69, 259-70.
13. Nomura M, Shimizu S, Sugiyama T, et al (2003). 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem, 278, 2058-65.
14. Patel T (2001). Increasing incidence and mortality of primary intrahepatic cholangiocarcinomain the United States. Hepatology, 33, 1353-7.
15. Porter GW, Khuri FR, Fu H (2006). Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Seminars Cancer Biol, 16, 193-202.
16. Samuel T, Weber HO, Rauch P, et al (2001). The G2/M regulator 14-3-3sigma prevents apoptosis through sequestration of Bax. J Biol Chem, 276, 45201-6.
17. Shankardas J, Senchyna M, Dimitrijevich SD (2008). Presence and distribution of 14-3-3 proteins in human ocular surface tissues. Mol Vis, 14, 2604-15.
18. Shu Y, Wang B, Wang J, Wang JM, Zou SQ (2011). Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma. World J Gastroenterol, 17, 3407-19.
19. Sinha P, Hutter G, Kottgen E, et al (1999). Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis, 20, 2952-60.
20. Sugiyama A, Miyagi Y, Komiya Y, et al (2003). Forced expression of antisense 14-3-3beta RNA suppresses tumor cell growth in vitro and in vivo. Carcinogenesis, 24, 1549-59.
21. Suzuki H, Itoh F, Toyota M, et al (2000). Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers. Cancer Res, 60, 4353-7.
22. Tio TL, Cheng J, Wijers OB, Sars PR, Tytgat GN (1991). Endosonographic TNM staging of extrahepatic bile duct cancer: comparison with pathological staging. Gastroenterology, 100, 1351-61.
23. Todd A, Cossons N, Aitken A, Price GB, Zannis-Hadjopoulos M (1998). Human cruciform binding protein belongs to the 14-3-3 family. Biochemistry, 37, 14317-25.
24. Tompkins RK, Thomas D, Wile A, Longmire WP Jr (1981). Prognostic factors in bile duct carcinoma: analysis of 96 cases. Ann Surg, 194, 447-57.
25. Toshima JY, Toshima J, Watanabe T, Mizuno K (2001). Binding of 14-3-3 beta regulates the kinase activity and subcellular localization of testicular protein kinase 1. J Biol Chem, 276, 43471-81.
26. Tzivion G, Gupta VS, Kaplun L, Balan V (2006). 14-3-3 proteins as potential oncogenes. Seminars in cancer biology. Semin Cancer Biol, 16, 203-13.
27. Wang Y, Jacobs C, Hook KE, et al (2000). Binding of 14-3-3 beta to the carboxyl terminus of Wee1 increases Wee1 stability, kinase activity, and G2-M cell population. Cell Growth Differ, 11, 211-9.
28. Wijaya I, Abdullah M (2011). Diagnosis and treatment update: cholangiocarcinoma. Acta Med Indones, 43, 212-5.
29. Wilker E, Yaffe MB (2004). 14-3-3 Proteins-a focus on cancer and human disease. J Mol Cell Cardiol, 37, 633-42.
30. Zang D, Li X, Zhang L (2010). 14-3-3 ? Overexpression and abnormal beta-catenin expression are associated with poor differentiation and progression in stage I non-small cell lung cancer. Clin Exp Med, 10, 221-8.
31. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell, 87, 619-28.
32. Zhai J, Lin H, Shamim M, Schlaepfer WW, Canete-Soler R (2001). Identification of a novel interaction of 14-3-3 with p190RhoGEF. J Biol Chem, 276, 41318-24.